PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10718341-1	2000	RH1 (2,5-diaziridinyl-3-(hydroxylmethyl)-6-methyl-1,4-benzoquinone) has shown preferential activity against human tumour cell lines which express high levels of DTD (EC 1.6.99.2; NAD(P)H:quinone oxidoreductase, NQO1, DT-diaphorase) and is a candidate for clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	crystallin zeta	Homo sapiens	187-209	
26596252-2	2016	A novel anticancer agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is designed to be activated by NAD(P)H: quinone oxidoreductase, an enzyme expressed at high levels in many types of tumors.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	25-85	crystallin zeta	Homo sapiens	132-154	
9865924-0	1998	A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	142-145	crystallin zeta	Homo sapiens	35-57	
26596252-2	2016	A novel anticancer agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is designed to be activated by NAD(P)H: quinone oxidoreductase, an enzyme expressed at high levels in many types of tumors.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	87-90	crystallin zeta	Homo sapiens	132-154